In the News: Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline. Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline.
In the News: AAVCOVID Partner Mass Eye and Ear Releases Preclinical Data on Single-Dose, Room Temperature-Stable COVID-19 Vaccine, and Announces Grant Award.
Aldevron is excited to share an update on our partner's progress regarding their AAVCOVID vaccine program. Mass Eye and Ear's novel gene-based vaccine strategy utilizes an adeno-associated virus (AAV) vector.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced today the addition of three reporter Self-amplifying RNA (saRNA) products to its growing catalog: AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™.
The Joint Session of the State of North Dakota’s 67th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.
Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.
Partnership with Harvard Scientists at Mass. Eye and Ear and Mass General Supports AAV Based Gene Therapies to Produce SARS-CoV-2 Vaccine
Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.
Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs
Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.
Today, at the State of Technology Conference with Senator Hoeven and the Fargo Moorhead West Fargo Chamber of Commerce, Aldevron announces completing the production of a DNA-based vaccine to combat malaria under a contract with the Naval Medical Research Center (NMRC). Aldevron, a leading contract manufacturer of plasmid DNA, proteins, and antibodies, produced three plasmid DNA constructs that have been delivered to NMRC in preparation for a phase I/II challenge study.